Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus FLUNISOLIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus FLUNISOLIDE.
BREO ELLIPTA vs FLUNISOLIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Corticosteroid with anti-inflammatory action; inhibits release of inflammatory mediators (e.g., histamine, leukotrienes), reduces eosinophil migration, and stabilizes mast cells. Suppresses cytokine production and adhesion molecule expression.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
50 mcg per nostril twice daily (total daily dose 200 mcg), via nasal spray.
None Documented
None Documented
Clinical Note
moderateFlunisolide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Gatifloxacin."
Clinical Note
moderateFlunisolide + Rosoxacin
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Rosoxacin."
Clinical Note
moderateFlunisolide + Levofloxacin
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Levofloxacin."
Clinical Note
moderateFlunisolide + Trovafloxacin
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal elimination half-life is 1.8 hours (range 1.3–2.5 h) after intravenous administration; clinically, endogenous suppression persists up to 24 h post-inhalation.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal (50%) as metabolites, fecal (40%) as metabolites via bile, <5% unchanged in urine.
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Trovafloxacin."